Coronavirus, from Plasma an anti Covid-19 treatment
Kedrion’s commitment to find a treatment from convalescent patient plasma
Annual Results 2019
Kedrion reaches a record high turnover of EUR 808.2 million and raises its REPORTED EBITDA to EUR 101.3 million
Kedrion – News Coronavirus (SARS-CoV-2)
"With regard to this epidemiological situation caused by Coronavirus Covid-19 in Italy, Kedrion informs that the company had taken action following the guidelines of International’s authorities, national and local, and doing everything was deemed necessary to protect the safety and security of the employees and to ensure continuous business operations. As the situation evolves continuously
SIMEST enters Kedrion Biopharma Inc. share capital
Released: 24/02/2020 – 17:16 GMTRNS Number: 9635DKedrion S.p.A. Milan, 24th February 2020 – Società Italiana per le Imprese all’Estero – SIMEST S.p.A. (SIMEST) has today become a minority shareholder of Kedrion Biopharma Inc. (Kedrion Biopharma) with a stake of 4.5% by means of payment of a capital increase of Kedrion Biopharma of USD equivalent of
Kedrion confirms closing with FSI SGR
Released: 15/11/2019 – 13:44 GMTRNS Number: 6238TKedrion S.p.A. Milan, 15th November 2019 – Following the press release dated 16th October 2019, Kedrion S.p.A. confirms the closing on today’s date of the transaction involving the acquisition by FSI SGR S.p.A. of Company shares from Sestant Internazionale S.p.A. at the value of Euro 100 million together
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy
Kedrion: clarifications concerning information published by the press
Released: 11/10/2019 – 09:12 GMTRNS Number: 6035PKedrion S.p.A In reference to the recent press releases regarding the entry of a new minority shareholder, Kedrion SpA confirms that there are pending negotiations but without any finalized agreement. The entry of a new partner would be consistent with the development strategy that the Group is pursuing at
Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY
On Sep 30, 2019 Kedrion Biopharma Inc. (Kedrion Biopharma) met another milestone towards transferring the drug manufacture of RhoGAM/MICRhoGAM from Ortho Clinical Diagnostics (OCD), Raritan, NJ to Kedrion Biopharma’s Melville, NY facility. A robust Prior Approval Supplement (PAS) package was submitted and acknowledged by the FDA for review. The Prescription Drug User Fee Act (PDUFA)
2019 First Half Results General Investor Call
Following the release of its 1H 2019 results Kedrion S.p.A. is pleased to arrange a General Investor Call Date & Time: Wednesday 11 September 2019 @ 09.30 UKT / 10.30 CET Dial-in: ITALY: +39 02 805 88 11UK: +44 121 281 8003FRANCE: +33 170918703GERMANY: +49 69255114451SPAIN: +34 917699497 The Company will be represented by:Simone Boaglio